BA vs PFE: Which Is the Better Buy?

Side-by-side comparison of The Boeing Company and Pfizer Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
The Boeing Company ยท Industrials
$217.63
+19.5% upside to fair value
Grade C
VS
Pfizer Inc. ยท Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric BA PFE
Current Price $217.63 $26.91
Fair Value Estimate $260.00 $35.00
Upside to Fair Value +19.5% +30.1%
Market Cap $170.9B $153.0B
Forward P/E 74.0x 9.5x
EV / EBITDA 28.4x 13.8x
Price / Sales 1.9x 2.4x
Price / FCF -88.2x 16.8x
Revenue Growth YoY +34.5% -1.6%
Gross Margin 4.8% 70.3%
Operating Margin -6.1% 24.7%
Return on Equity 41.0% 9.0%
Dividend Yield 0.2% 6.4%
FCF Yield -1.1% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
BA โ€” The Boeing Company
The Boeing Company is the world's largest aerospace manufacturer operating across commercial airplanes, defense and space, global services, and Boeing Capital. After years of losses stemming from the 737 MAX crisis, production disruptions, and regulatory setbacks, Boeing posted its first profitable year in 2025 with net income of $2.2 billion on revenue of $89.5 billion, a 34.5% revenue increase โ€ฆ
PFE โ€” Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seagโ€ฆ
Accumulation Zones
Metric BA PFE
Zone Low $195.00 $25.00
Zone High $221.00 $29.00
In Buy Zone? Yes Yes
โ† BA Research    PFE Research โ†’    All Research